Report: Unsupported Drug Price Hikes Cost U.S. $815M in 2023
TL;DR
In 2023, drugmakers increased prices on five widely used drugs without new clinical evidence, costing U.S. patients and insurers an additional $815 million, according to a report by the Institute for Clinical and Economic Review. The largest spending increase was for Biktarvy, an HIV treatment by Gilead Sciences, which saw a 5.9% wholesale price hike, resulting in $359 million more in spending. Gilead claims some study data were overlooked or rejected, challenging the report's findings.
Topics:businesshealth#drug-pricing#gilead-sciences#health#healthcare-costs#hiv-treatment#pharmaceutical-industry
- Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds STAT
- Unsupported price hikes added $815M to US drug spending in 2023 KSL.com
- ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases FiercePharma
- Handful of 'unsupported' drug price increases added $800M to US costs, ICER claims Endpoints News
- ICER report reveals $815M in 'unsupported' drug price hikes FirstWord Pharma
Want the full story? Read the original reporting
Read on STAT